|
AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan’s Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds. ‘Datopotamab deruxtecan is the only investigational therapy to show a clinically meaningful survival improvement in patients with previously treated nonsquamous non-small cell lung cancer versus docetaxel, which has long been unsurpassed in this post-targeted treatment and post-immunotherapy setting,’ says Susan Galbraith, executive vice president of oncology research & development at AstraZeneca. ‘These results reinforce the potential for datopotamab deruxtecan to replace conventional chemotherapy in this late-line setting and underscore our confidence in ongoing trials evaluating this therapy in first-line lung cancer,’ she continues. Dato-DXd was discovered by Daiichi Sankyo, and is being jointly-developed alongside AstraZeneca. Current Daiichi stock price: up 3.4% at JP¥5,627.00 each in Tokyo on Monday 12-month change: up 24% Current Astra stock price: 12,296.00 pence, closed down 0.9% on Friday 12-month change: up 6.9% Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
